Du är här

2014-05-23

Active Biotech: Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opin

Jerusalem&Lund,
Sweden, May 23, 2014
- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ
OMX NORDIC: ACTI) announced today that the Committee for Medicinal Products
for Human Use's (CHMP) confirmed its January 23, 2014 opinion to recommend
against approval for the treatment of relapsing-remitting multiple sclerosis
(RRMS) in the European Union (EU) at this time.

Both companies remain committed to the NERVENTRA®(laquinimod) clinical
development program for multiple sclerosis (MS) and are focused on evaluating
the CHMP feedback to determine potential next steps.

"We are disappointed with the outcome of the re-examination and will be
working with the EMA to make NERVENTRA available to multiple sclerosis
patients in the EU," said Michael Hayden, President of Global R&D and Chief
Scientific Officer. "We believe NERVENTRA has a favorable risk-benefit
profile and the potential to fulfill an unmet need for a treatment that
decreases disability progression, and protects against brain volume loss, two
important goals in the management of MS."

To further confirm the benefits of NERVENTRA on disability progression, Teva
is conducting the CONCERTO trial, the largest MS trial with disability
progression as the primary endpoint. The ongoing CONCERTO trial is the third
Phase III study in RRMS and explores daily doses of NERVENTRA 0.6 mg and 1.2
mg. In addition, Teva is investigating the potential of NERVENTRA in
progressive forms of MS. The first trial for this indication is planned to be
initiated soon.

About NERVENTRA®
NERVENTRA is a once-daily oral, investigational, CNS-active immunomodulator
with a novel mechanism of action being developed for the treatment of
relapsing-remitting MS (RRMS) and progressive forms of MS. In extensive
non-clinical and clinical studies, NERVENTRA has demonstrated both
anti-inflammatory and neuroprotective properties and effects that have been
shown to provide clinically meaningful results. The global Phase III clinical
development program evaluating NERVENTRA in MS includes two pivotal studies,
ALLEGRO and BRAVO. A third Phase III NERVENTRA trial, CONCERTO, is evaluating
two doses of the investigational product (0.6mg and 1.2mg) in approximately
2,100 patients for up to 24 months. The primary outcome measure will be time
to confirmed disability progression as measured by the EDSS, making CONCERTO
the largest MS clinical trial with disability progression as the primary
endpoint.

The safety profile of NERVENTRA is based on 2,645 MS patients that have been
exposed to NERVENTRA for a total duration of 7,491 subject years, with a
maximal duration of seven years. Very common or important adverse reactions
include headache, abdominal pain, back and neck pain, appendicitis, and mild,
asymptomatic laboratory abnormalities, including liver enzyme elevations,
hematological changes, and elevation of CRP or fibrinogen levels.

In addition to the MS clinical studies, studies are planned to evaluate the
efficacy, safety and tolerability of NERVENTRA in other neurodegenerative
diseases including Huntington's disease.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic
drug maker, with a global product portfolio of more than 1,000 molecules and
a direct presence in approximately 60 countries. Teva's Specialty Medicines
businesses focus on CNS, respiratory, oncology, pain, and women's health
therapeutic areas as well as biologics. Teva currently employs approximately
45,000 people around the world and reached $20.3 billion in net revenues in
2013.

About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is
laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis. Also
tasquinimod for the treatment of prostate cancer, with a unique mode of
action, is in pivotal phase. In addition, laquinimod has concluded Phase II
development for Crohn's and Lupus. The company has two additional projects in
clinical development, ANYARA primarily for the treatment of renal cell cancer
and the orally administered compound paquinimod (57-57) for systemic
sclerosis. Please visit www.activebiotech.com for more information.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act
of 1995:
This release contains forward-looking statements, which are based on
management's current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products; competition for our
innovative products, especially COPAXONE®(including competition from
orally-administered alternatives, as well as from potential purported generic
equivalents); the possibility of material fines, penalties and other
sanctions and other adverse consequences arising out of our ongoing FCPA
investigations and related matters; our ability to achieve expected results
from the research and development efforts invested in our pipeline of
specialty and other products; our ability to reduce operating expenses to the
extent and during the timeframe intended by our cost reduction program; our
ability to identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions; the
extent to which any manufacturing or quality control problems damage our
reputation for quality production and require costly remediation; our
potential exposure to product liability claims that are not covered by
insurance; increased government scrutiny in both the U.S. and Europe of our
patent settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the intellectual
property rights of our specialty medicines; the effects of reforms in
healthcare regulation and pharmaceutical pricing, reimbursement and coverage;
governmental investigations into sales and marketing practices, particularly
for our specialty pharmaceutical products; uncertainties related to our
recent management changes; the effects of increased leverage and our
resulting reliance on access to the capital markets; any failure to recruit
or retain key personnel, or to attract additional executive and managerial
talent; adverse effects of political or economical instability, major
hostilities or acts of terrorism on our significant worldwide operations;
interruptions in our supply chain or problems with internal or third-party
information technology systems that adversely affect our complex
manufacturing processes; significant disruptions of our information
technology systems or breaches of our data security; competition for our
generic products, both from other pharmaceutical companies and as a result of
increased governmental pricing pressures; competition for our specialty
pharmaceutical businesses from companies with greater resources and
capabilities; decreased opportunities to obtain U.S. market exclusivity for
significant new generic products; potential liability in the U.S., Europe and
other markets for sales of generic products prior to a final resolution of
outstanding patent litigation; any failures to comply with complex Medicare
and Medicaid reporting and payment obligations; the impact of continuing
consolidation of our distributors and customers; significant impairment
charges relating to intangible assets and goodwill; potentially significant
increases in tax liabilities; the effect on our overall effective tax rate of
the termination or expiration of governmental programs or tax benefits, or of
a change in our business; variations in patent laws that may adversely affect
our ability to manufacture our products in the most efficient manner;
environmental risks; and other factors that are discussed in our Annual
Report on Form 20-F for the year ended December 31, 2013 and in our other
filings with the U.S. Securities and Exchange Commission. Forward-looking
statements speak only as of the date on which they are made and we assume no
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish
Securities Market Act:

This press release contains certain forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from
any future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or
publicly release any revisions to forward-looking statements to reflect
events, circumstances or changes in expectations after the date of this press
release.

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This
information was provided to the media for publication 08:30 a.m. CEST on May
23, 2014.

Teva and Active Biotech to continue with the development of NERVENTRA
http://hugin.info/1002/R/1788087/614173.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

HUG#1788087

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.